deltatrials
Completed PHASE2 NCT00123773

Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

Sponsor: AHS Cancer Control Alberta

Conditions Kidney Neoplasms Multiple Myeloma Ovarian Neoplasms Sarcoma Testicular Neoplasms
Interventions Positron Emission Tomography
Updated 5 times since 2017 Last updated: Feb 24, 2016 Started: Apr 30, 2004 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

Listed as NCT00123773, this PHASE2 trial focuses on Kidney Neoplasms and Multiple Myeloma and remains completed. Sponsored by AHS Cancer Control Alberta, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AHS Cancer Control Alberta
  • Cross Cancer Institute
Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Edmonton, Canada